NTRA News and Press, Natera Inc. From 11/08/23

2023-11-08 16:12:13 ET More on Natera Natera: Cash Burn Remains A Concern Natera: Strong Growth Amidst Profitability Challenges Canaccord sees solid Q3 earnings for medtech; likes Quanterix, Natera, Guardant Natera prevails in patent battle as Supreme Court d...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the third quarter ended September 30, 2023. Recent Strategic and Financial Highlights Generated total revenues of $268.3 million in the third quarter of 2023, compared to $210...

Study to evaluate effectiveness of switching treatment to elacestrant in early breast cancer based on the detection of molecular relapse with Signatera ™ Approximately 1,900 early-stage breast cancer patients to be screened at 120+ sites in Europe Natera, Inc. (NASDAQ...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

Natera Inc. (NTRA) is expected to report $-0.96 for Q3 2023

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will participate in the following investor conferences in November. A live webcast and audio archive of each event may be accessed through the investor relations section of the Natera website at ...

Study found 1 in 5 patients was positive for a genetic cause of CKD, 1 in 2 positive patients received a new or reclassified diagnosis, and 1 in 3 positive patients had a change in treatment plan Diagnostic yield and utility exceed clinical precedents for implementation of routine genetic...

2023-10-29 17:28:12 ET More on Guardant Health, Natera, etc. Natera: Cash Burn Remains A Concern Guardant Health: Peeling Back Economic Layers, Compressed Market Values Appear Justified Pacific Biosciences: Looks Appealing In The Fast-Growing Long-Read Sequencing Mar...

2023-10-25 14:17:58 ET Summary Today, we circle back on Natera, Inc., a fast-growing diagnostic testing concern. The company continues to rack up impressive sales growth, but its cash burn remains a primary concern. With Natera, Inc. stock down some 30% from recent highs, is n...

Builds on published evidence with twice as many patients and disease-free survival data extended to 24 months Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced updated data from the GALAXY arm of the CIRCULATE-Japan trial further showcasing the a...